company background image
KAEF

Kimia Farma (Persero) IDX:KAEF Stock Report

Last Price

Rp1.47k

Market Cap

Rp8.1t

7D

-1.0%

1Y

-39.5%

Updated

24 May, 2022

Data

Company Financials
KAEF fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance4/6
Financial Health2/6
Dividends0/6

KAEF Stock Overview

PT Kimia Farma (Persero) Tbk produces and sells medicines, herbal medicines, iodine, salts, quinine and their derivative products, and vegetable oils in Indonesia.

Kimia Farma (Persero) Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Kimia Farma (Persero)
Historical stock prices
Current Share PriceRp1,465.00
52 Week HighRp3,670.00
52 Week LowRp1,375.00
Beta-0.33
1 Month Change-1.01%
3 Month Change-32.49%
1 Year Change-39.46%
3 Year Change-56.79%
5 Year Change-48.23%
Change since IPO597.62%

Recent News & Updates

Shareholder Returns

KAEFID PharmaceuticalsID Market
7D-1.0%1.3%2.2%
1Y-39.5%1.9%17.3%

Return vs Industry: KAEF underperformed the ID Pharmaceuticals industry which returned 1.9% over the past year.

Return vs Market: KAEF underperformed the ID Market which returned 17.3% over the past year.

Price Volatility

Is KAEF's price volatile compared to industry and market?
KAEF volatility
KAEF Average Weekly Movement6.2%
Pharmaceuticals Industry Average Movement3.7%
Market Average Movement6.2%
10% most volatile stocks in ID Market12.0%
10% least volatile stocks in ID Market2.9%

Stable Share Price: KAEF is not significantly more volatile than the rest of ID stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: KAEF's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
181711,906Verdi Budidarmohttps://kimiafarma.co.id

PT Kimia Farma (Persero) Tbk produces and sells medicines, herbal medicines, iodine, salts, quinine and their derivative products, and vegetable oils in Indonesia. The company operates through Manufacturing, Distribution, Retail, and Other Services segments. It also manufactures and sells generic, ethical, license and narcotic medicines, and over the counter medicines, health equipment, raw materials, medicines, medical devices, and cosmetics.

Kimia Farma (Persero) Fundamentals Summary

How do Kimia Farma (Persero)'s earnings and revenue compare to its market cap?
KAEF fundamental statistics
Market CapRp8.14t
Earnings (TTM)Rp302.27b
Revenue (TTM)Rp12.86t

26.9x

P/E Ratio

0.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
KAEF income statement (TTM)
RevenueRp12.86t
Cost of RevenueRp8.81t
Gross ProfitRp4.05t
Other ExpensesRp3.74t
EarningsRp302.27b

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)54.42
Gross Margin31.47%
Net Profit Margin2.35%
Debt/Equity Ratio110.0%

How did KAEF perform over the long term?

See historical performance and comparison

Dividends

0.09%

Current Dividend Yield

2%

Payout Ratio

Valuation

Is Kimia Farma (Persero) undervalued compared to its fair value and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


26.92x

Price to Earnings (PE) ratio

Share Price vs. Fair Value

Below Fair Value: KAEF (IDR1465) is trading above our estimate of fair value (IDR10.98)

Significantly Below Fair Value: KAEF is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: KAEF is poor value based on its Price-To-Earnings Ratio (26.9x) compared to the ID Pharmaceuticals industry average (20.7x).

PE vs Market: KAEF is poor value based on its Price-To-Earnings Ratio (26.9x) compared to the ID market (18.3x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate KAEF's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: KAEF is good value based on its Price-To-Book Ratio (1.1x) compared to the ID Pharmaceuticals industry average (2.5x).


Future Growth

How is Kimia Farma (Persero) forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


15.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Kimia Farma (Persero) has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Kimia Farma (Persero) performed over the past 5 years?

Past Performance Score

4/6

Past Performance Score 4/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-24.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: KAEF has high quality earnings.

Growing Profit Margin: KAEF's current net profit margins (2.4%) are higher than last year (0.2%).


Past Earnings Growth Analysis

Earnings Trend: KAEF's earnings have declined by 24.3% per year over the past 5 years.

Accelerating Growth: KAEF's earnings growth over the past year (1613.7%) exceeds its 5-year average (-24.3% per year).

Earnings vs Industry: KAEF earnings growth over the past year (1613.7%) exceeded the Pharmaceuticals industry 11.7%.


Return on Equity

High ROE: KAEF's Return on Equity (4%) is considered low.


Financial Health

How is Kimia Farma (Persero)'s financial position?

Financial Health Score

2/6

Financial Health Score 2/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: KAEF's short term assets (IDR6,303.5B) exceed its short term liabilities (IDR5,980.2B).

Long Term Liabilities: KAEF's short term assets (IDR6,303.5B) exceed its long term liabilities (IDR4,548.1B).


Debt to Equity History and Analysis

Debt Level: KAEF's net debt to equity ratio (99.6%) is considered high.

Reducing Debt: KAEF's debt to equity ratio has increased from 36.1% to 110% over the past 5 years.

Debt Coverage: KAEF's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: KAEF's interest payments on its debt are not well covered by EBIT (1.7x coverage).


Balance Sheet


Dividend

What is Kimia Farma (Persero) current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage


0.086%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: KAEF's dividend (0.086%) isn’t notable compared to the bottom 25% of dividend payers in the ID market (1.14%).

High Dividend: KAEF's dividend (0.086%) is low compared to the top 25% of dividend payers in the ID market (4.14%).


Stability and Growth of Payments

Stable Dividend: KAEF is not paying a notable dividend for the ID market, therefore no need to check if payments are stable.

Growing Dividend: KAEF is not paying a notable dividend for the ID market, therefore no need to check if payments are increasing.


Earnings Payout to Shareholders

Earnings Coverage: KAEF is not paying a notable dividend for the ID market.


Cash Payout to Shareholders

Cash Flow Coverage: KAEF is paying a dividend but the company has no free cash flows.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.0yrs

Average management tenure


CEO

Verdi Budidarmo (52 yo)

7.92yrs

Tenure

Dr. Verdi Budidarmo, Apt serves as President Director at PT Kimia Farma (Persero) Tbk since September 18, 2019. He served as President Commissioner at PT Phapros Tbk since August 26, 2019 until 2021. He ha...


Leadership Team

Experienced Management: KAEF's management team is considered experienced (3 years average tenure).


Board Members

Experienced Board: KAEF's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

PT Kimia Farma (Persero) Tbk's employee growth, exchange listings and data sources


Key Information

  • Name: PT Kimia Farma (Persero) Tbk
  • Ticker: KAEF
  • Exchange: IDX
  • Founded: 1817
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: Rp8.137t
  • Shares outstanding: 5.55b
  • Website: https://kimiafarma.co.id

Number of Employees


Location

  • PT Kimia Farma (Persero) Tbk
  • Jl. Veteran No.9
  • Gambir
  • Jakarta
  • Jakarta Raya
  • 10110
  • Indonesia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/24 00:00
End of Day Share Price2022/05/24 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.